WMIC: Caliper bolsters product line

Caliper Life Sciences has introduced a series of XenoLight Rediject reagents for in vivo imaging systems at the 2009 World Molecular Imaging Congress (WMIC) in Montreal this week.

Rediject D-Luciferin Ultra is the latest in an expanding range of XenoLight reagents, according to the Hopkinton, Mass.-based firm. It is supplied in a ready-to-inject format, pre-formulated with a tracking agent in order to monitor injection quality and minimize data variability.

Using this reagent in an in vivo imaging system, researchers can validate their techniques and generate more reproducible data in less time, according to Caliper.

In the past year, the company has also introduced two imaging platforms, including the IVIS Kinetic, which uses video-rate imaging to image biological processes in real-time, and the IVIS Lumina XR, Caliper's first instrument to integrate fluorescence, bioluminescence and x-ray capabilities into a single system.

Around the web

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.